Journal of clinical medicineOct 27, 2026

Semaglutide use in people with obesity and psoriasis over 18 months in real-life settings

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Oct 28, 2026

Abstract

A significant mean reduction of 4.25 points in the PASI score was observed in 33 obese patients with mild-to-moderate psoriasis treated with semaglutide over 18 months.

Adherence to semaglutide prescriptions was 94%, with most patients receiving a last recorded dose of 1.0 mg.
A mean decrease of 4.15 kg/m² in BMI was noted, alongside significant improvements in all metabolic parameters.
Inflammatory markers also showed significant decreases, with CRP dropping from 5.47 to 2.69 mg/L and ESR from 17.76 to 11.64 mm/h.
Over 57.6% of patients experienced mild and transitory gastrointestinal reactions, but no discontinuation or cutaneous reactions were reported.
These findings provide insights into semaglutide's potential role in treating psoriasis in obese patients, though larger studies are needed for validation.

Simplified

Psoriasis is often associated with obesity and type 2 diabetes mellitus (T2DM) due to a common low-grade chronic inflammatory mechanism amplified by metabolic dysfunction. Biologics have revolutionized psoriasis treatment, but patients with obesity show reduced responses and higher discontinuation rates. Glucagon-like peptide-1 receptor agonists-such as semaglutide-may enhance the efficacy of psoriasis care; however, data are limited in this context. We presented a retrospective analysis of our single-center real-world experience with 33 obese patients (24 men and 9 women) affected by mild (n = 19, 57.6%) or moderate (n = 14, 42.4%) psoriasis and treated with semaglutide over 18 months. Adherence to the semaglutide prescription was 94% (range 88-99%), with most patients (54.5%) having a last recorded dose of 1.0 mg. A significant mean reduction of 4.25 points in the PASI score (from 9.31 ± 1.54 to 5.05 ± 0.88; p < 0.001) was reported, followed by a mean decrease of 4.15 kg/m² in BMI (from 32.53 ± 1.92 to 28.38 ± 1.59 kg/m²; p < 0.001) and significant improvements in all metabolic parameters. In addition, there was a significant decrease in inflammatory markers (CRP decreased from 5.47 ± 1.69 to 2.69 ± 0.94 mg/L, and ESR from 17.76 ± 4.22 to 11.64 ± 2.83 mm/h). More than fifty-seven percent (57.6%) of patients experienced mild and transitory gastrointestinal reactions, but no cases of discontinuation or cutaneous reaction occurred. Data provide additional insights into the role of semaglutide in patients with mild-to-moderate psoriasis. Large-scale, multicenter studies are needed to validate long-term results.

Full Text

Full text is available at the source.

View Full Text ↗

Semaglutide use in people with obesity and psoriasis over 18 months in real-life settings

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief